Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03 2024 - 8:00AM
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”)
(NASDAQ: FATE), a clinical-stage biopharmaceutical company
dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune disorders, today announced that
the Company will present at the 23rd Annual Needham Virtual
Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET.
A live webcast, if recorded, of each presentation can be
accessed under “Events & Presentations” in the Investors
section of the Company’s website at www.fatetherapeutics.com. The
archived webcast will be available on the Company’s website shortly
after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical
company dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune disorders. Using its
proprietary iPSC product platform, the Company has established a
leadership position in creating multiplexed-engineered iPSC lines
and in the manufacture and clinical development of off-the-shelf,
iPSC-derived cell products. The Company’s pipeline includes
iPSC-derived natural killer (NK) cell and T-cell product
candidates, which are selectively designed, incorporate novel
synthetic controls of cell function, and are intended to deliver
multiple therapeutic mechanisms to patients. Fate
Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor
Relations, Inc.212.362.1200christina.tartaglia@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024